Loading
ELI LILLY & Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Aug 2025.
ELI LILLY & Co: what insiders have been doing
ELI LILLY & Co, founded in 1875, is a Healthcare & Pharma company based in Indianapolis, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 125 filings were filed, from 30 insiders.
Only sales appear on the open market, 28 sales in all totalling €587.0M, filed by 5 insiders. The totals do not cover 1 filing with an undisclosed amount. One trade stands out by size: a sale of €147.5M from Lilly Endowment Inc, disclosed on 3 November 2025.
Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 125 filings is above the norm. Our records for ELI LILLY & Co go back to 2016, with 12 purchases and 233 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 65.18 bn USD and net income at 20.64 bn USD, and the dividend at 6.23 USD per share.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
801
Thresholds
n/a
Buy Volume
€4M
12 ops. · all time
Sell Volume
€3B
233 ops. · all time
Who traded when
BuySaleLilly Endowment Inc44 sales
Donald A. Zakrowski6 sales
Yuffa Ilya3 sales
Skovronsky Daniel1 buy1 sale
Anat Hakim1 sale
Gabrielle Sulzberger1 buy
+7 other insiders
Since the insiders bought
- +71.2%Entry 603.10 · Close at T+365 1,032.80
- +71.2%Entry 603.10 · Close at T+365 1,032.80
- +77.3%Entry 577.10 · Close at T+365 1,023.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 15 October 2026
Declarations801 total
305,000 shares@ US$1,208.740.034% mcap26.0% of flowCommon StockSEC144:0000316011-26-000033
300,000 shares@ US$1,157.490.033% mcap33.0% of flowCommon StockSEC144:0000316011-26-000031
10.659 shares@ US$1,164.890.0000% mcap0.7% of flowCommon StockSEC:0001310215-26-000017:0
8.513 shares@ US$1,164.890.0000% mcap0.8% of flowCommon StockSEC:0000059478-26-000089:0
13.664 shares@ US$1,164.890.0000% mcap1.6% of flowCommon StockSEC:0000059478-26-000091:0
4.257 shares@ US$1,164.890.0000% mcap0.7% of flowCommon StockSEC:0001262388-26-000018:0
17 shares0Common StockSEC:0002032089-26-000004:0
12 shares0Common StockSEC:0002032089-26-000004:1
216 shares0Common StockSEC:0001955972-26-000008:0
13 shares0Common StockSEC:0001861052-26-000006:0
8.382 shares@ US$1,183.160.0000% mcap0.8% of flowCommon StockSEC:0000059478-26-000085:0
13.453 shares@ US$1,183.160.0000% mcap1.6% of flowCommon StockSEC:0000059478-26-000087:0
4.191 shares@ US$1,183.160.0000% mcap0.7% of flowCommon StockSEC:0001262388-26-000016:0
6,500 shares@ US$1,175.100.0007% mcap25.1% of flowCommon StockSEC:0001786054-26-000006:0
10.495 shares@ US$1,183.160.0000% mcap0.7% of flowCommon StockSEC:0001310215-26-000015:0
6,500 shares@ US$1,175.100.0007% mcap100.0% of flowEli Lilly Common StockSEC144:0001628280-26-057430
2,000 shares@ US$1,185.010.0002% mcap15.6% of flowCommon StockSEC:0000059478-26-000083:0
2,000 shares@ US$1,185.710.0002% mcap100.0% of flowCommonSEC144:0001950047-26-007881
5,000 shares@ US$1,190.000.0005% mcap13.5% of flowCommon StockSEC:0001685556-26-000006:0
10,000 shares@ US$1,190.000.0011% mcap26.9% of flowCOMMONSEC144:0001949846-26-000477
981 shares0Common StockSEC:0002032089-26-000002:0
438.707 shares@ US$1,148.840.0000% mcap100.0% of flowCommon StockSEC:0002032089-26-000002:1
10.826 shares@ US$1,146.900.0000% mcap0.7% of flowCommon StockSEC:0001310215-26-000013:0
13.878 shares@ US$1,146.900.0000% mcap1.6% of flowCommon StockSEC:0000059478-26-000068:0
8.647 shares@ US$1,146.900.0000% mcap0.8% of flowCommon StockSEC:0000059478-26-000066:0
25 of 801 declarations
About ELI LILLY & Co
Eli Lilly and Company (NYSE: LLY) is a major U.S.-listed pharmaceutical company headquartered in Indianapolis, Indiana, United States. The company traces its origins to 1876, when Colonel Eli Lilly founded a drug manufacturing business in Indianapolis; Lilly was then incorporated in Indiana in 1901 to succeed that enterprise. Today, Lilly reports in a single operating segment: human pharmaceutical products. Its business model is built around research, development, manufacturing, and global commercialization of innovative medicines. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8))
From an equity analysis perspective, Lilly’s portfolio is now dominated by cardiometabolic growth engines, while also retaining meaningful exposure to oncology, immunology, and other specialty therapeutic areas. Key marketed products include Mounjaro and Zepbound, which have become core growth drivers, alongside Trulicity, Humalog, Verzenio, Taltz, Jardiance through a collaboration, Jaypirca, and other assets. The company’s pipeline is also closely watched, especially orforglipron, its oral GLP-1 candidate that has become one of the most strategically important programs in the industry. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8))
Read moreShow less
In competitive terms, Lilly is one of the global leaders in incretin-based therapies, competing in a highly contested market with Novo Nordisk and other pharmaceutical peers. Its competitive edge comes from strong clinical execution, a broad late-stage pipeline, manufacturing scale, and a commercial footprint that has allowed it to capture substantial demand in diabetes and obesity. Lilly’s 2024 annual report indicates that Mounjaro, Trulicity, and Zepbound together represented a very large share of total revenue, underscoring how central the cardiometabolic franchise has become to the investment case. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8))
Geographically, Lilly has a global presence with sales in the United States and outside the United States, and it continues to invest across major developed markets and selected high-growth regions. Recent company news has reinforced the growth narrative: in 2025 and 2026, Lilly reported multiple positive clinical and regulatory milestones for orforglipron, expanded access and pricing initiatives for Zepbound, and label expansion progress for Jaypirca. Taken together, these developments support the view of Lilly as a high-quality large-cap healthcare franchise with secular growth drivers, strong innovation momentum, and an increasingly important position in global metabolic medicine. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
